American family physician最新文献_第9页

Consider a Formal Exercise Prescription as Initial Therapy for Patients With Symptoms of Depression. 考虑为有抑郁症状的患者开具正式的运动处方，作为初始疗法。

IF 3.8 3区医学

American family physician Pub Date : 2024-06-01

Allen F Shaughnessy

引用次数: 0

Gestational Diabetes Mellitus, Acetaminophen Overdose, Congenital Syphilis, e-Cigarettes, Acne Vulgaris, Newborn Birthmarks. 妊娠糖尿病、对乙酰氨基酚过量、先天性梅毒、电子烟、痤疮、新生儿胎记。

IF 3.8 3区医学

American family physician Pub Date : 2024-06-01

引用次数: 0

Testosterone Replacement Therapy for Male Hypogonadism. 男性性腺功能减退症的睾酮替代疗法。

IF 3.8 3区医学

American family physician Pub Date : 2024-06-01

Joel J Heidelbaugh, Aleksandr Belakovskiy

{"title":"Testosterone Replacement Therapy for Male Hypogonadism.","authors":"Joel J Heidelbaugh, Aleksandr Belakovskiy","doi":"","DOIUrl":"","url":null,"abstract":"Testosterone deficiency, or male hypogonadism, is a clinical syndrome that can be defined as persistently low serum testosterone levels in the setting of symptoms consistent with testosterone deficiency. Studies suggest that testosterone replacement therapy may improve sexual function, depressive symptoms, bone density, and lean body mass. Evidence is conflicting regarding its effect on cardiovascular events and mortality. Although prior studies suggested that testosterone replacement therapy increased the risk of cardiovascular disease, a large, randomized trial showed that it does not increase the risk of myocardial infarction or stroke, even in patients at high risk. After a detailed discussion of the potential benefits and risks through shared decision-making, testosterone replacement therapy should be considered for men with testosterone deficiency to correct selected symptoms and induce and maintain secondary sex characteristics. Treatment method should take into consideration patient preference, pharmacokinetics, potential for medication interactions, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving testosterone replacement therapy for symptom improvement, potential adverse effects, and adherence. Serum testosterone, hematocrit, and prostate-specific antigen levels should be measured at baseline and at least annually in men 40 years or older receiving testosterone replacement therapy. (Am Fam Physician. 2024;109(6):543-549.","PeriodicalId":7713,"journal":{"name":"American family physician","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single Intramuscular Dose of Nirsevimab Reduces Likelihood of Hospitalization Due to RSV in Average-Risk Infants During First Year of Life. 单次肌肉注射 Nirsevimab 可降低出生后第一年平均风险婴儿因 RSV 而住院的可能性。

IF 3.8 3区医学